התחל במצב לא מקוון עם האפליקציה Player FM !
פודקאסטים ששווה להאזין
בחסות
![We Have The Receipts podcast artwork](https://cdn.player.fm/images/37350108/series/3hptiqPGSZRELxyS/32.jpg 32w, https://cdn.player.fm/images/37350108/series/3hptiqPGSZRELxyS/64.jpg 64w, https://cdn.player.fm/images/37350108/series/3hptiqPGSZRELxyS/128.jpg 128w, https://cdn.player.fm/images/37350108/series/3hptiqPGSZRELxyS/256.jpg 256w, https://cdn.player.fm/images/37350108/series/3hptiqPGSZRELxyS/512.jpg 512w)
![We Have The Receipts podcast artwork](/static/images/64pixel.png)
1 Love Is Blind S8: Pods & Sober High Thoughts with Courtney Revolution & Meg 1:06:00
01_02 Latest and greatest in metastatic colon cancer – mAbs, MSI status, sidedness and controversies
Manage episode 324500957 series 3335024
1. Background on molecular targeted agents
2. VEGF-inhibitors
3. EGFR inhibition
4. Left vs Right sided colon cancer
5. MSI-H/dMMR status
Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.
Some highlighted references recommended to read related to this specific episode:
1. Botrel TEA et al. BMC Cancer. 2016;16(1):1-19. doi:10.1186/S12885-016-2734-Y/FIGURES/5
2. Deng T et al. Medical Oncol 2013 30:4. 2013;30(4):1-5. doi:10.1007/S12032-013-0752-Z
3. Hurwitz H et al. NEJM. 2009;350(23):2335-2342. doi:10.1056/NEJMOA032691
4. Booth CM, Goodman AM. Nature Rev Clinl Oncol 2021 18:11. 2021;18(11):673-674. doi:10.1038/s41571-021-00550-9
5. Booth C. J Clin Oncol. 2008;26(28):4693-4694. doi:10.1200/JCO.2008.18.8060
6. Saltz LB et al. J Clin Oncol. 2008;26(12):2013-2019. doi:10.1200/JCO.2007.14.9930
7. Stathopoulos GP et al. Oncology. 2010;78(5-6):376-381. doi:10.1159/000320520
8. Tang W et al. J Clin Oncol. 2020;38(27):3175-3184. doi:10.1200/JCO.20.00174
9. Giantonio BJ et al. J Clin Oncol. 2007;25(12):1539-1544. doi:10.1200/JCO.2006.09.6305
10. van Cutsem E et al. NEJM. 2009;360(14):1408-1417.
11. Cutsem E van, et al. J Clin Oncol. doi:10.1200/JCO.2010.28.15_SUPPL.3570
12. Bokemeyer C et al. Eur J Cancer. 2012;48(10):1466-1475. doi:10.1016/J.EJCA.2012.02.057
13. Tejpar S et al. JAMA Oncol. 2017;3(2):194-201. doi:10.1001/JAMAONCOL.2016.3797
14. Venook AP et al. JAMA. 2017;317(23):2392-2401. doi:10.1001/JAMA.2017.7105
15. Maughan TS et al. The Lancet. 2011;377(9783):2103-2114
16. Lenz HJ et al. J Clin Oncol. 2019;37(22):1876-1885. doi:10.1200/JCO.18.02258
17. Venook A et al. Ann Oncology. 2014;25(2):ii112. doi:10.1093/ANNONC/MDU193.19
18. Shiu KK et al. J Clin Oncol https://doi.org/101200/JCO2021393_suppl6. 2021;39(3_suppl):6-6. doi:10.1200/JCO.2021.39.3_SUPPL.6
19. André T et al. NEJM 2020;383(23):2207-2218.
20. Jonker DJ al. NEJM. 2009;2(11):2040-2048. doi:10.1056/NEJMOA071834
21. Brulé SY et al. Eur J Cancer. 2015;51(11):1405-1414. doi:10.1016/J.EJCA.2015.03.015
22. Tol J et al. NEJM. 2009;360(6):563-572.
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.
49 פרקים
01_02 Latest and greatest in metastatic colon cancer – mAbs, MSI status, sidedness and controversies
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
Manage episode 324500957 series 3335024
1. Background on molecular targeted agents
2. VEGF-inhibitors
3. EGFR inhibition
4. Left vs Right sided colon cancer
5. MSI-H/dMMR status
Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.
Some highlighted references recommended to read related to this specific episode:
1. Botrel TEA et al. BMC Cancer. 2016;16(1):1-19. doi:10.1186/S12885-016-2734-Y/FIGURES/5
2. Deng T et al. Medical Oncol 2013 30:4. 2013;30(4):1-5. doi:10.1007/S12032-013-0752-Z
3. Hurwitz H et al. NEJM. 2009;350(23):2335-2342. doi:10.1056/NEJMOA032691
4. Booth CM, Goodman AM. Nature Rev Clinl Oncol 2021 18:11. 2021;18(11):673-674. doi:10.1038/s41571-021-00550-9
5. Booth C. J Clin Oncol. 2008;26(28):4693-4694. doi:10.1200/JCO.2008.18.8060
6. Saltz LB et al. J Clin Oncol. 2008;26(12):2013-2019. doi:10.1200/JCO.2007.14.9930
7. Stathopoulos GP et al. Oncology. 2010;78(5-6):376-381. doi:10.1159/000320520
8. Tang W et al. J Clin Oncol. 2020;38(27):3175-3184. doi:10.1200/JCO.20.00174
9. Giantonio BJ et al. J Clin Oncol. 2007;25(12):1539-1544. doi:10.1200/JCO.2006.09.6305
10. van Cutsem E et al. NEJM. 2009;360(14):1408-1417.
11. Cutsem E van, et al. J Clin Oncol. doi:10.1200/JCO.2010.28.15_SUPPL.3570
12. Bokemeyer C et al. Eur J Cancer. 2012;48(10):1466-1475. doi:10.1016/J.EJCA.2012.02.057
13. Tejpar S et al. JAMA Oncol. 2017;3(2):194-201. doi:10.1001/JAMAONCOL.2016.3797
14. Venook AP et al. JAMA. 2017;317(23):2392-2401. doi:10.1001/JAMA.2017.7105
15. Maughan TS et al. The Lancet. 2011;377(9783):2103-2114
16. Lenz HJ et al. J Clin Oncol. 2019;37(22):1876-1885. doi:10.1200/JCO.18.02258
17. Venook A et al. Ann Oncology. 2014;25(2):ii112. doi:10.1093/ANNONC/MDU193.19
18. Shiu KK et al. J Clin Oncol https://doi.org/101200/JCO2021393_suppl6. 2021;39(3_suppl):6-6. doi:10.1200/JCO.2021.39.3_SUPPL.6
19. André T et al. NEJM 2020;383(23):2207-2218.
20. Jonker DJ al. NEJM. 2009;2(11):2040-2048. doi:10.1056/NEJMOA071834
21. Brulé SY et al. Eur J Cancer. 2015;51(11):1405-1414. doi:10.1016/J.EJCA.2015.03.015
22. Tol J et al. NEJM. 2009;360(6):563-572.
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.
49 פרקים
Alle episoder
×![Artwork](/static/images/128pixel.png)
1 04_08 Metastatic Renal Cell Carcinoma 24:16
![Artwork](/static/images/128pixel.png)
1 04_07 Localized Renal Cell Carcinoma 25:15
![Artwork](/static/images/128pixel.png)
1 04_06 Metastatic Urothelial Cancer 24:33
![Artwork](/static/images/128pixel.png)
1 04_05 Muscle Invasive Bladder Cancer 29:16
![Artwork](/static/images/128pixel.png)
1 01_14 Ampullary Carcinoma (Mini Discussion) 10:59
![Artwork](/static/images/128pixel.png)
1 04_04 Castrate Resistant Metastatic Prostate Cancer 24:50
![Artwork](/static/images/128pixel.png)
1 04_03 Metastatic Castrate Sensitive Prostate Cancer 29:02
![Artwork](/static/images/128pixel.png)
1 04_02 Adjuvant Options for Prostate Cancer 28:41
![Artwork](/static/images/128pixel.png)
1 04_01 Fundamentals of Localized Prostate Cancer 31:59
![Artwork](/static/images/128pixel.png)
1 03_13 Head and Neck Cancer – Locally advanced and metastatic 37:18
![Artwork](/static/images/128pixel.png)
1 03_12 Head and Neck Cancer – Background and adjuvant considerations 23:28
![Artwork](/static/images/128pixel.png)
1 03_11 Mesothelioma and a bit of Large Cell Neuroendocrine Carcinoma 29:40
ברוכים הבאים אל Player FM!
Player FM סורק את האינטרנט עבור פודקאסטים באיכות גבוהה בשבילכם כדי שתהנו מהם כרגע. זה יישום הפודקאסט הטוב ביותר והוא עובד על אנדרואיד, iPhone ואינטרנט. הירשמו לסנכרון מנויים במכשירים שונים.